Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revefenacin in Chinese COPD patients
NCT05046795Phase 3Completed
- Sponsor
- Mylan
- Start
- Nov 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of revefenacin in chronic obstructive pulmonary disease (COPD), sponsored by Mylan. Started Nov 2021; status: completed.
02
Drugs
revefenacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05046795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05046795.